share_log

Kaisa Health Group Holdings' (HKG:876) Profits May Not Reveal Underlying Issues

Kaisa Health Group Holdings' (HKG:876) Profits May Not Reveal Underlying Issues

佳兆业健康集团控股公司 (HKG: 876) 的利润可能不会显示潜在问题
Simply Wall St ·  2023/10/02 20:44

Kaisa Health Group Holdings Limited (HKG:876) just released a solid earnings report, and the stock displayed some strength. While the profit numbers were good, our analysis has found some concerning factors that shareholders should be aware of.

佳兆业健康集团控股有限公司 (HKG: 876) 刚刚发布了一份稳健的收益报告,该股表现出一定的走强。尽管利润数字不错,但我们的分析发现了一些股东应该注意的令人担忧的因素。

Check out our latest analysis for Kaisa Health Group Holdings

查看我们对佳兆业健康集团控股的最新分析

earnings-and-revenue-history
SEHK:876 Earnings and Revenue History October 3rd 2023
香港联交所:876 收益和收入记录 2023 年 10 月 3 日

The Impact Of Unusual Items On Profit

不寻常物品对利润的影响

To properly understand Kaisa Health Group Holdings' profit results, we need to consider the HK$38m gain attributed to unusual items. We can't deny that higher profits generally leave us optimistic, but we'd prefer it if the profit were to be sustainable. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. Which is hardly surprising, given the name. We can see that Kaisa Health Group Holdings' positive unusual items were quite significant relative to its profit in the year to June 2023. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

为了正确理解佳兆业健康集团控股的盈利业绩,我们需要考虑归因于不寻常项目的3,800万港元收益。我们不能否认更高的利润通常会让我们感到乐观,但如果利润是可持续的,我们更愿意这样做。当我们计算成千上万家上市公司的数字时,我们发现,在给定年份中,不寻常的项目通常会带来提振 第二年重复。考虑到这个名字,这并不奇怪。我们可以看到,佳兆业健康集团控股的积极异常项目相对于其截至2023年6月的一年中的利润来说相当可观。在其他条件相同的情况下,这可能会使法定利润成为基础收益能力的糟糕指导。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Kaisa Health Group Holdings.

注意: 我们始终建议投资者检查资产负债表的实力。点击此处查看我们对佳兆业健康集团控股的资产负债表分析。

Our Take On Kaisa Health Group Holdings' Profit Performance

我们对佳兆业健康集团控股盈利表现的看法

As we discussed above, we think the significant positive unusual item makes Kaisa Health Group Holdings' earnings a poor guide to its underlying profitability. As a result, we think it may well be the case that Kaisa Health Group Holdings' underlying earnings power is lower than its statutory profit. On the bright side, the company showed enough improvement to book a profit this year, after losing money last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. If you want to do dive deeper into Kaisa Health Group Holdings, you'd also look into what risks it is currently facing. To that end, you should learn about the 3 warning signs we've spotted with Kaisa Health Group Holdings (including 1 which is concerning).

正如我们上面所讨论的那样,我们认为这一重大积极的不寻常项目使佳兆业健康集团控股公司的收益无法指导其基础盈利能力。因此,我们认为佳兆业健康集团控股公司的基本盈利能力很可能低于其法定利润。好的一面是,该公司在去年亏损之后,表现出足够的改善,足以在今年实现盈利。本文的目标是评估我们在多大程度上可以依靠法定收益来反映公司的潜力,但还有很多事情要考虑。如果你想更深入地了解佳兆业健康集团控股公司,你还需要研究它目前面临的风险。为此,你应该了解 3 个警告标志 我们发现了佳兆业健康集团控股公司(包括一个令人担忧的公司)。

Today we've zoomed in on a single data point to better understand the nature of Kaisa Health Group Holdings' profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

今天,我们放大了单个数据点,以更好地了解佳兆业健康集团控股公司的利润性质。但是,还有很多其他方法可以告知你对一家公司的看法。有些人认为高股本回报率是优质业务的好兆头。所以你不妨看看这个 免费的 一系列拥有高股本回报率的公司,或者这份内部人士正在买入的股票清单。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?担心内容吗? 取得联系 直接和我们在一起。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St 的这篇文章本质上是笼统的。 我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。 它不构成买入或卖出任何股票的建议,也没有考虑您的目标或财务状况。我们的目标是为您提供由基本面数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。简而言之,华尔街在上述任何股票中都没有头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发